CJC-1295 (No DAC) / Ipamorelin — 2 mg / 2 mg

The requested blend contains two separate signaling peptides rather than growth hormone itself. CJC-1295 without DAC generally denotes modified GRF(1–29), while ipamorelin is a synthetic pentapeptide acting through the growth-hormone-secretagogue pathway. Core Peptides identifies its product as a no-DAC combination and discusses a complementary effect on pituitary growth-hormone release, with ipamorelin portrayed as relatively selective for GH over other pituitary or stress-related hormonal responses. [1]

The original ipamorelin pharmacology study examined cultured rat pituitary cells, rats, and swine. Investigators reported substantial GH release and, in their swine experiments, substantially less stimulation of ACTH and cortisol than with GHRP-2 or GHRP-6. These findings describe ipamorelin under the study’s conditions, not a general guarantee about a blended product or every human endocrine response. [2] FDA’s 2024 review documents online marketing of CJC-1295/ipamorelin and claims of synergy, while identifying inconsistent specification of which CJC form is being discussed. [3] That distinction matters because prolonged CJC-1295 exposure findings typically concern the DAC-linked compound. The requested no-DAC blend should therefore be described as a proposed dual-secretagogue research pairing, without assigning it the duration or outcomes of the longer-acting analogue.